SAN DIEGO, February 9, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.
Site Search
Recent News
- BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis
- selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
- Meet selectION, Inc. at the BIO International Convention in Boston, on June 5th to 8th, 2023